Biohaven .(US:BHVN) Prnewswireยท2025-09-04 12:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's product candidates and their regulatory prospects [1][2]. Group 1: Allegations - The complaint alleges that during the class period from March 24, 2023, to May 14, 2025, Biohaven's statements regarding the regulatory prospects of its product candidate, troriluzole, were overstated [1]. - It is claimed that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were also overstated [1]. - The revelations of these issues are likely to have a significant negative impact on Biohaven's business and financial condition [1]. Group 2: Class Action Details - Shareholders who purchased shares of BHVN during the specified class period are encouraged to register for the class action, with a deadline set for September 12, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. - There is no cost or obligation for shareholders to participate in this case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].